The effect of L-arginine in non-alcoholic fatty liver

Investigating the effect of L-arginine on patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230409057859N1

Enrollment

Registered

2023-04-18

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: The first intervention group will receive lifestyle modification and L-arginine drug (Perarin Pars Company) at a dose of 2 grams per day for 3 months. Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with non-alcoholic fatty liver Patients over 18 years old

Exclusion criteria

Exclusion criteria: • pregnant women • Patients with liver cirrhosis • Patients with viral and autoimmune hepatitis • Patients with advanced heart and kidney diseases • Patients with celiac disease Wilson's patients

Design outcomes

Primary

Measure	Time frame
Improvement of hepatic steatosis. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: fibro scan.;Alanine Aminotransferease (ALT) allevation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: blood test- biochemical marker.;Fibrosis Index -for liver based in 4 factors (Fib-4) alleviation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: Mathematical formula fib-4.	—

Measure

Time frame

Improvement of hepatic steatosis. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: fibro scan.;Alanine Aminotransferease (ALT) allevation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: blood test- biochemical marker.;Fibrosis Index -for liver based in 4 factors (Fib-4) alleviation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: Mathematical formula fib-4.

—

Secondary

Measure	Time frame
BMI alleviation. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Height and weight ratio formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Rashvand

Shahid Beheshti University of Medical Sciences

dr.h.rashvand@gmail.com+98 21 2243 2525

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026